Centrally acting antiadrenergic (versus unexposed) updated on 03-11-2025

Coarctation of aorta

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14245
R55973
Fisher - Centrally acting antiadrenergics (Controls unexposed, disease free), 2017 Coarctation of the aorta early pregnancy case control unexposed, disease free excluded Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 1.94 [0.81;4.63]
excluded (control group)
6/48   -/- - 48
ref
S14247
R55990
Fisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 Coarctation of the aorta early pregnancy case control unexposed, sick Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 1.26 [0.50;3.19] 6/48   -/- - 48
ref
Total 1 studies 1.26 [0.50;3.18] 0 48
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Fisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017Fisher - Centrally acting ant..., 2017 1 1.26[0.50; 3.19]-480%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 1.26[0.50; 3.18]-48 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 Type of controls unexposed, sickunexposed, sick 1.26[0.50; 3.18]-48 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 Tags Adjustment   - Yes  - Yes 1.26[0.50; 3.18]-48 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.26[0.50; 3.18]-48 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 All studiesAll studies 1.26[0.50; 3.18]-48 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 14245

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.94[0.81; 4.64]-48 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, disease free), 2017 1 unexposed, sick controlsunexposed, sick controls 1.26[0.50; 3.18]-48 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 10.510.01.0